Editorial – Page 49 – ExecEdge

FIGS Third Quarter Net Revenue Increases 10.7%

FIGS Third Quarter Net Revenue Increases 10.7%

By Daniella Parra FIGS, Inc. (NYSE: FIGS), a healthcare community lifestyle brand, reported net revenue rose to 142.4 million, an increase of 10.7% YoY in Q3 with active customers increasing 19.6% to 2.6 million. The company said the adjusted EBITDA...

Portillo’s Third Quarter Revenue Climbs 10% on New Restaurants

Portillo’s Third Quarter Revenue Climbs 10% on New Restaurants

By Thomas Green Portillo’s Inc. (Nasdaq: PTLO) said third quarter revenue rose 10.4% to $166.8 million as it added new restaurants. The Chicago-style, fast-casual chain’s operating income increased $4.5 million to $15.1 million this quarter and Restaurant-Level Adjusted EBITDA increased...

Betterware Reports Third Quarter Increase in Profit Margin

Betterware Reports Third Quarter Increase in Profit Margin

By Daniella Parra Betterware de Mexico S.A.P.I. de C.V. (NASDAQ: BWMX) said Ebitda in the third quarter rose 10 percent from a year earlier. Ebitda was Ps. 328M with a 3.3pp margin expansion, while revenue showed stability for the fourth...

American Seafoods CSO Fitzgerald on Sustainability Trends

American Seafoods CSO Fitzgerald on Sustainability Trends

Tim Fitzgerald, American Seafoods Chief Sustainability Officer By Exec Edge Editorial Staff Sustainability is ubiquitous in business. But consumers may not realize how much effort goes into making seafood sustainable, from fisheries management to ships to innovation. Exec Edge spoke...

Sparrow Pharmaceuticals Begins Phase 2 Study for ACS Treatment

Sparrow Pharmaceuticals Begins Phase 2 Study for ACS Treatment

By Daniella Parra Sparrow Pharmaceuticals said it initiated a Phase 2 ACSpire study for SPI-62, a potent HSD-1 inhibitor, targeting autonomous cortisol secretion (ACS). ACS results from excessive cortisol production due to benign adrenal tumors and can lead to severe...

Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results

Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results

By Daniella Parra Apollomics Inc. (Nasdaq: APLM) unveiled results from the KUNPENG clinical trial at ESMO 2023, showing vebreltinib’s potential as a treatment for cancers with MET alterations, they said. The Phase 2 trial by Apollomics’ partner, Avistone Biotechnology Ltd.,...

Input your search keywords and press Enter.